growing prevalence of cancer cases is driving the Cancer Supportive Care Market
Technavio analyzes that the Cancer Supportive Care Market is expected to grow at a CAGR of 4.3% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 6259.3 million.There are various factors that contribute to the growth of the market. The cancer supportive care market is experiencing significant growth due to the increasing prevalence of cancer cases worldwide. According to the World Health Organization, there will be approximately 19.3 million new cancer cases and nearly 10.0 million cancer deaths in 2020. This rising incidence of cancer necessitates comprehensive and effective supportive care services to improve patients' quality of life and manage symptoms. The market for cancer supportive care is anticipated to expand in response to this growing demand.
Anemia, a prevalent condition characterized by insufficient healthy red blood cells or hemoglobin, is a significant challenge in childhood cancer patients undergoing oncology treatment. With chemotherapy being a common therapy, approximately 100% of patients experience mild anemia, and over 75% develop severe symptoms. Hemoglobin, a major component of red blood cells responsible for oxygen binding, becomes deficient, leading to fatigue and impaired organ function due to insufficient oxygen supply. Targeted molecule therapies and opioids are essential tools in managing severe anemia symptoms, mitigating the public health crisis caused by this debilitating side effect.
Know which region is leading the market growth by requesting a sample report
Cancer Supportive Care Market Segmentation
As per our research findings, here are some of the key competitors that are leading the industry
Find out what is trending in the market by accessing the free PDF report
The Cancer Supportive Care Market encompasses various treatments and interventions to manage adverse effects and toxicities of cancer therapies, including Granulocyte colony-stimulating factors and antiemetics. Breast cancer patients in hospitals and online pharmacies receive supportive care during post-therapy, addressing chemotherapy-induced side effects such as anemia, hair loss, and pain. Healthcare administration, palliative care specialists, and pain care specialists collaborate in patient-centric care. Drug development in pharmaceuticals advances innovative therapies like erythropoiesis-stimulating agents (ESAs) and antibody-drug combinations for metastatic colorectal cancer, anemia, and triple-negative breast cancer. The aging and geriatric population's increasing cancer prevalence necessitates personalized medicine, biosimilars, and generic medications to improve accessibility and affordability. Cancer treatment toxicities are addressed through clinical trials and the development of new supportive care strategies.
The Cancer Supportive Care Market is a significant segment of the global Healthcare Equipment Market, according to Technavio's market research. This market encompasses companies and products dedicated to the research and development (R&D) of antiemetics and other supportive care solutions for breast cancer patients. The parent Healthcare Equipment Market entails manufacturers of various diagnostic equipment and devices, including capital equipment, instruments, implants, accessories, and consumables, used for disease diagnosis, monitoring, and treatment. Technavio calculates the market size based on the combined revenue generated by these manufacturers across therapy areas. The Healthcare Equipment Industry consists of Devices, which include advanced, differentiated, and clinically tested data-driven devices, essential for cancer supportive care.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted